Kingmed Diagnostics
Kingmed Diagnostics is a third-party medical inspection service provider.
Kingmed Diagnostics, established in 1994, is a third-party medical inspection and pathological diagnosis service provider, mainly engaging in third-party medical assessment and pathological diagnosis business and providing leading medical diagnosis information integration services and and pathological diagnosis outsourcing services for medical institutions at all levels across the country. Founded by Guangzhou Medical University, it went public in September 2017. Its main shareholder is Liang Yaoming, and peer companies are Transtek Medical Electronics and Inkon Life Technology.
Medtronic's world's first self expanding pulmonary valve was first-class recalled
EqualOcean Sector Quarterly Report - Healthcare Sectors
To help worldwide investors keep track of what is happening in each industry or sector and the related hot spots, we launched the EqualOcean Sector Quarterly Report series, which gathers notable information and statistics in each quarter.
Apr 07, 2022 01:44 PM
Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use
Research
Healthcare, Consumer Staples, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Healthcare, Technology, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
Research
Healthcare, Technology, Consumer DiscretionaryLow-Carbon Industry Expansion - Key Studies From Chinese Companies
The new crown inactivated vaccine of Sinopharm Zhongsheng Omicron mutant was approved clinically.
Yanye said that its Xinguan oral drug s-217622 can quickly eliminate the virus
Bojian abandons Alzheimer's disease drug aduhelm and goes public in the EU
Upside foods, a cell meat enterprise, received US $400 million in financing, the highest single transaction in the industry
Jinyu medicine: we are actively cooperating in the investigation of Jinyu incident in Zhengzhou
Hillhouse-Backed SMO Stock ClinPlus Climbs 67% on IPO Day
ClinPlus, a Chinese clinic site management company, has completed the initial public offering process and is now the first SMO company to be listed on the Chinese A-share market. After the IPO, Hillhouse is holding 1.5 percent of the company's stock.
May 18, 2022 05:38 AM
Lingbo Yihui Raises Tens of Mns of CNY in a Pre-Series A Round
With the full implementation of the marketing authorization holder (MAH) system and the rapid growth in China's medical device industry, the contract research organization (CRO) and contract development and manufacturing organization (CDMO) markets will continue to grow.
May 17, 2022 09:28 PM
Gilid signed an agreement with science and technology to deepen strategic cooperation in the areas of chronic hepatitis B, hepatitis C and HIV infection.
Back to Hong Kong, Chinese concept stocks rose collectively, and Wanguo data rose 17.5%